Clinical Research Directory

Key Inclusion Criteria: * Signed informed consent. * Relapsed or refractory CD20+ diffuse large B-cell lymphoma, mantle cell lymphoma or indolent lymphoma. * The patient should have been treated with at least two lines of therapy and have no curative treatment option, specifically * Relapsed or refractory CD20+ B-cell lymphoma that are not eligible to receive clinically approved CD19-directed CAR T cell treatment. * Relapsed or refractory CD20+ B-cell lymphoma who are CD19 negative. * Relapsed or refractory B-cell lymphoma who relapse after CD19 CAR T cell treatment. * In phase I age \>18 years, in phase II all ages * Measurable disease per Lugano classification. * Performance status ECOG 0-2. * Adequate bone marrow function as evidenced by: * Absolute neutrophil count (ANC) ≥ 1x10\^9/l/L * Platelet ≥ 50x 10\^9/l * Absolute lymphocyte count ≥ 0,1x10\^9/L * Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by: * Creatinine clearance (Cockcroft Gault) ≥ 30 mL/min * Serum Alanine aminotransferase/Aspartate aminotransferase (ALT/AST) ≤ 2.5 Upper limit of normal (ULN) and S-Bilirubin \<1.5x UNL * Cardiac ejection fraction ≥ 40% * Functional venous for administration of IMP. * Fertile individuals must consent to use contraceptives during participation in the trial. Exclusion Criteria: * Other CD20-positive lymphomas i.e Burkitt lymphoma, primary CNS lymphoma, plasmablastic lymphoma or CLL transformed to DLBCL/HGBL (Richter transformation) * Any significant medical or psychiatric illness that would prevent the subject from giving informed consent or from following the study procedures. * Known human immunodeficiency virus (HIV) infection. * Impending organ-compromising disease. * Rapidly progressing disease * Active and/or severe infection (e.g., tuberculosis, sepsis and opportunistic infections, active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection. * Other serious underlying medical conditions, which, in the Investigator's judgment, could impair the ability of the subject to perform the treatment. * Treatment with an investigational product within 30 days prior to enrolment * Potential sign of hypersensitivity reaction to tocilizumab or any of the agents used in this study * Systemic corticosteroid treatment (\>10mg/day) \<5 days prior to IMP treatment or \<7 days prior leukapheresis. * Pregnancy